

Andrea Aglitti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2270827/publications.pdf>

Version: 2024-02-01

32
papers

1,061
citations

623188

14
h-index

580395

25
g-index

33
all docs

33
docs citations

33
times ranked

2312
citing authors

#	ARTICLE	IF	CITATIONS
1	Olmesartan-induced enteropathy: More than one entity?. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	0
2	Viral hepatitis: Milestones, unresolved issues, and future goals. <i>World Journal of Gastroenterology</i> , 2021, 27, 4603-4638.	1.4	21
3	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <i>Metabolomics</i> , 2021, 17, 12.	1.4	37
4	Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. <i>Liver International</i> , 2020, 40, 1032-1041.	1.9	44
5	Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study. <i>Liver Cancer International</i> , 2020, 1, 12-24.	0.2	2
6	Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program. <i>Digestive and Liver Disease</i> , 2020, 52, 541-546.	0.4	21
7	The diagnostic conundrum in non-alcoholic fatty liver disease. <i>Exploration of Medicine</i> , 2020, 1, .	1.5	6
8	THU-168-Real-life effectiveness and safety of glecaprevir/pibrentasvir in HCV infected patients with chronic kidney disease. <i>Journal of Hepatology</i> , 2019, 70, e236.	1.8	1
9	Real-life efficacy and safety of glecaprevir/pibrentasvir in HCV-infected patients with chronic kidney disease. <i>GastroHep</i> , 2019, 1, 166.	0.3	2
10	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	1.7	44
11	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3415.	1.2	90
12	HCV point-of-care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy. <i>Liver International</i> , 2019, 39, 1845-1851.	1.9	11
13	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , 2019, 39, 1852-1859.	1.9	31
14	Preclinical evaluation of Endothelial Dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles in NAFLD. <i>Digestive and Liver Disease</i> , 2019, 51, e27-e28.	0.4	1
15	HCV-Ab sero-prevalence in persons who inject drugs in a Province of Southern Italy: results of a screening program. <i>Digestive and Liver Disease</i> , 2019, 51, e17.	0.4	0
16	Hepatitis C virus prevalence in a cohort of jailbirds in a city of Southern Italy. <i>Digestive and Liver Disease</i> , 2019, 51, e59.	0.4	0
17	FRI-326-Preclinical evaluation of endothelial dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles. <i>Journal of Hepatology</i> , 2019, 70, e539.	1.8	0
18	Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease. <i>Digestive and Liver Disease</i> , 2019, 51, e66.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 310-317.	0.4	47
20	Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis. <i>Antiviral Therapy</i> , 2018, 23, 129-138.	0.6	33
21	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with direct acting antivirals: A prospective multicenter Italian study. <i>Digestive and Liver Disease</i> , 2018, 50, 34-35.	0.4	0
22	High efficacy of direct-acting antiviral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1705-1712.	1.9	26
23	Metabolomics in the progression of non alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2018, 50, 18.	0.4	2
24	Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. <i>Hepatology</i> , 2018, 67, 48-55.	3.6	76
25	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study. <i>Journal of Hepatology</i> , 2018, 68, S86.	1.8	2
26	Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1 infection. <i>Journal of Hepatology</i> , 2018, 68, S292.	1.8	7
27	Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-12.	1.9	28
28	Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	1.9	447
29	Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. <i>PLoS ONE</i> , 2017, 12, e0178473.	1.1	79
30	A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure. <i>Digestive and Liver Disease</i> , 2016, 48, e233.	0.4	0
31	Liver biopsy in Type 2 Diabetes Mellitus: Steatohepatitis represents the sole feature of liver damage. <i>Digestive and Liver Disease</i> , 2016, 48, e237.	0.4	0
32	Impact of SVR and Type 2 Diabetes Mellitus on liver stiffness and liver functionality in HCV infected patients with severe liver disease treated with DAA: A real life study. <i>Digestive and Liver Disease</i> , 2016, 48, e234.	0.4	0